Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis
Abstract Background Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We condu...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4268-y |
| _version_ | 1819012476485763072 |
|---|---|
| author | Hao Peng Ling-Long Tang Xu Liu Lei Chen Wen-Fei Li Yan-Ping Mao Yuan Zhang Li-Zhi Liu Li Tian Ying Guo Ying Sun Jun Ma |
| author_facet | Hao Peng Ling-Long Tang Xu Liu Lei Chen Wen-Fei Li Yan-Ping Mao Yuan Zhang Li-Zhi Liu Li Tian Ying Guo Ying Sun Jun Ma |
| author_sort | Hao Peng |
| collection | DOAJ |
| description | Abstract Background Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We conducted this retrospective study to address this. Methods We identified 296 patients with newly diagnosed LA-NPC at Sun Yat-Sen University Cancer Center between January 2012 and May 2015. Patients were treated by IC with CCRT or RT and CTX/NTZ was delivered during IC or radiotherapy. Survival outcomes and toxicities between different arms were compared. Results In total, there were 149 patients in the investigational arm and 147 in control arm. The 3-year disease-free survival, overall survival, distant metastasis-free survival and locoregional relapse-free survival rates for investigational arm vs. control arm were 84.3% vs. 74.3% (P = 0.027), 94.0% vs. 92.1% (P = 0.673), 88.0% vs. 81.8% (P = 0.147) and 93.3% vs. 88.0% (P = 0.093). Multivariate analysis revealed patients in the control arm achieved significantly worse disease-free survival (HR, 1.497; 95% CI, 1.016–2.206; P = 0.026) compared with those in the investigational arm; however, no significant difference was identified for other endpoints. Patients in the investigational arm experienced more grade 3–4 skin reaction (15.4% vs. 2.0%, P < 0.001) and mucositis (10.1% vs. 3.4%, P = 0.022) during induction phase, but less skin reaction (5.4% vs. 25.9%, P < 0.001) and mucositis (24.8% vs. 36.7%, P = 0.026) during RT. Conclusions Our findings suggested that CTX/NTZ concurrently with IC may be a more effective and promising strategy for patients with LA-NPC receiving intensity-modulated radiotherapy. |
| first_indexed | 2024-12-21T01:44:40Z |
| format | Article |
| id | doaj.art-c062a637262f4a03941503960cc03d50 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-21T01:44:40Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-c062a637262f4a03941503960cc03d502022-12-21T19:20:04ZengBMCBMC Cancer1471-24072018-03-011811910.1186/s12885-018-4268-yAnti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysisHao Peng0Ling-Long Tang1Xu Liu2Lei Chen3Wen-Fei Li4Yan-Ping Mao5Yuan Zhang6Li-Zhi Liu7Li Tian8Ying Guo9Ying Sun10Jun Ma11Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineImaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineImaging Diagnosis and Interventional Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Clinical Trials Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer MedicineAbstract Background Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We conducted this retrospective study to address this. Methods We identified 296 patients with newly diagnosed LA-NPC at Sun Yat-Sen University Cancer Center between January 2012 and May 2015. Patients were treated by IC with CCRT or RT and CTX/NTZ was delivered during IC or radiotherapy. Survival outcomes and toxicities between different arms were compared. Results In total, there were 149 patients in the investigational arm and 147 in control arm. The 3-year disease-free survival, overall survival, distant metastasis-free survival and locoregional relapse-free survival rates for investigational arm vs. control arm were 84.3% vs. 74.3% (P = 0.027), 94.0% vs. 92.1% (P = 0.673), 88.0% vs. 81.8% (P = 0.147) and 93.3% vs. 88.0% (P = 0.093). Multivariate analysis revealed patients in the control arm achieved significantly worse disease-free survival (HR, 1.497; 95% CI, 1.016–2.206; P = 0.026) compared with those in the investigational arm; however, no significant difference was identified for other endpoints. Patients in the investigational arm experienced more grade 3–4 skin reaction (15.4% vs. 2.0%, P < 0.001) and mucositis (10.1% vs. 3.4%, P = 0.022) during induction phase, but less skin reaction (5.4% vs. 25.9%, P < 0.001) and mucositis (24.8% vs. 36.7%, P = 0.026) during RT. Conclusions Our findings suggested that CTX/NTZ concurrently with IC may be a more effective and promising strategy for patients with LA-NPC receiving intensity-modulated radiotherapy.http://link.springer.com/article/10.1186/s12885-018-4268-yNasopharyngeal carcinomaInduction chemotherapyCetuximabNimotuzumabIntensity-modulated radiotherapyPrognosis |
| spellingShingle | Hao Peng Ling-Long Tang Xu Liu Lei Chen Wen-Fei Li Yan-Ping Mao Yuan Zhang Li-Zhi Liu Li Tian Ying Guo Ying Sun Jun Ma Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis BMC Cancer Nasopharyngeal carcinoma Induction chemotherapy Cetuximab Nimotuzumab Intensity-modulated radiotherapy Prognosis |
| title | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis |
| title_full | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis |
| title_fullStr | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis |
| title_full_unstemmed | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis |
| title_short | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis |
| title_sort | anti egfr targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma a big data intelligence platform based analysis |
| topic | Nasopharyngeal carcinoma Induction chemotherapy Cetuximab Nimotuzumab Intensity-modulated radiotherapy Prognosis |
| url | http://link.springer.com/article/10.1186/s12885-018-4268-y |
| work_keys_str_mv | AT haopeng antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT linglongtang antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT xuliu antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT leichen antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT wenfeili antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT yanpingmao antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT yuanzhang antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT lizhiliu antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT litian antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT yingguo antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT yingsun antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis AT junma antiegfrtargetedtherapydeliveredbeforeversusduringradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaabigdataintelligenceplatformbasedanalysis |